Table 1 Baseline and clinical characteristics of study patients
Non-rituximab group | Rituximab group | P-value | |
|---|---|---|---|
Number of patients | 1588 (75.3) | 522 (24.7) | |
Mean age (years) | 47.1 ± 11.2 | 47.6 ± 11.5 | 0.37 |
Female sex | 610 (39.3) | 275 (49.3) | < 0.01 |
Diabetes mellitus | 325 (20.5) | 114 (21.8) | 0.51 |
Hypertension | 1376 (86.6) | 459 (87.9) | 0.50 |
Body mass index (kg/m2) | 24.4 ± 6.5 | 23.0 ± 7.8 | 0.64 |
Cause of rituximab treatment | |||
XM positive | – | 126 (24.1) | |
ABO- i | – | 331 (63.4) | |
XM positive & ABO- i | – | 51 (9.8) | |
Rejection treatment | – | 14 (2.7) | |
Calcineurin inhibitor | 0.66 | ||
Prograf | 1165 (73.4) | 388 (74.3) | |
Cyclosporin | 423 (26.6) | 134 (25.7) | |
Induction | < 0.01 | ||
No induction | 81 (5.1) | 0 (0.0) | |
ATG | 121 (7.6) | 3 (0.6) | |
Basiliximab | 1386 (87.3) | 519 (99.4) | |
Previous transplant | 114 (7.2) | 51 (9.8) | < 0.01 |
Duration of dialysis (months) | 41.8 ± 54.3 | 23.4 ± 35.7 | < 0.01 |
Donor | < 0.01 | ||
Deceased donor | 439 (27.6) | 4 (0.8) | |
Living related | 761 (47.9) | 275 (52.7) | |
Living unrelated | 388 (24.5) | 243 (46.5) | |
HLA-A,B,DR mismatch | 3.0 ± 1.7 | 3.4 ± 1.7 | < 0.01 |
PRA class I | 10.3 ± 22.7 | 18.0 ± 30.8 | < 0.01 |
PRA class II | 10.9 ± 24.0 | 18.9 ± 32.4 | < 0.01 |
CMV viremia | 393 (35.7) | 223 (43.1) | < 0.01 |
PCP after transplant | 18 (1.1) | 20 (3.8) | < 0.01 |
PCP related mortality | 1 (0.1%) | 5 (1.0%) | < 0.01 |
Mortality among PCP patients (n = 38) | 1 (5.6%) | 5 (25.0%) | 0.18 |